Compare COGT & STWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | STWD |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.4B |
| IPO Year | 2018 | 2009 |
| Metric | COGT | STWD |
|---|---|---|
| Price | $37.03 | $18.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $36.21 | $20.00 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 10.58% |
| EPS Growth | N/A | ★ 4.55 |
| EPS | N/A | ★ 1.15 |
| Revenue | $7,871,000.00 | ★ $1,844,289,000.00 |
| Revenue This Year | N/A | $283.44 |
| Revenue Next Year | $1,733.58 | $17.66 |
| P/E Ratio | ★ N/A | $15.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.24 | $16.90 |
| 52 Week High | $43.73 | $20.99 |
| Indicator | COGT | STWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 62.82 |
| Support Level | $36.08 | $17.58 |
| Resistance Level | $37.58 | $18.62 |
| Average True Range (ATR) | 1.58 | 0.24 |
| MACD | 0.15 | 0.11 |
| Stochastic Oscillator | 58.32 | 95.27 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Starwood Property Trust Inc is a real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans, commercial mortgage-backed securities, and other real estate investments in the U.S., Australia, and Europe. The company has four reportable business segments: Commercial and Residential Lending, Infrastructure Lending, Property, and Investing and Servicing. The majority of its revenue is generated from the Commercial and Residential Lending segment, which engages mainly in originating, acquiring, financing, and managing commercial first mortgages, non-agency residential mortgages (residential loans), commercial mortgage-backed securities (CMBS), residential mortgage-backed securities (RMBS), and other real estate and related debt investments.